Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

被引：59

作者：

Akimoto, Hayato ^{[1
]}

Negishi, Akio ^{[1
]}

Oshima, Shinji ^{[1
]}

Wakiyama, Haruna ^{[1
]}

Okita, Mitsuyoshi ^{[2
]}

Horii, Norimitsu ^{[2
,3
]}

Inoue, Naoko ^{[2
,3
]}

Ohshima, Shigeru ^{[2
,3
]}

Kobayashi, Daisuke ^{[1
]}

机构：

[1] Josai Univ, Fac Pharm & Pharmaceut Sci, Dept Analyt Pharmaceut & Informat, Sakado, Saitama, Japan

[2] Josai Univ Pharm, Saitama, Japan

[3] Josai Univ, Fac Pharm & Pharmaceut Sci, Lab Pharm Management, Sakado, Saitama, Japan

来源：

AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS | 2020年 / 35卷

关键词：

Alzheimer disease; dementia; type 2 diabetes mellitus; antidiabetics; FDA adverse event reporting system; GLUCAGON-LIKE PEPTIDE-1; BLOOD-BRAIN-BARRIER; DIABETES-MELLITUS; GLYCEMIC CONTROL; AMYLOID-BETA; INSULIN-RESISTANCE; COGNITIVE FUNCTION; OLDER-ADULTS; METFORMIN; ROSIGLITAZONE;

D O I：

10.1177/1533317519899546

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (>= 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

引用

页数：11

共 58 条

[1]

Alzheimer's Association, 2016, ALZHEIMERS DEMENT, V12, P459, DOI DOI 10.1016/J.JALZ.2016.03.001

[2] A curated and standardized adverse drug event resource to accelerate drug safety research [J].